6 results
- To determine the response based on Palmo-plantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at the end of treatment (week 24), or at the latest assessment for patients who withdraw prematurely
Primary Objective: * To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantSecondary Objectives:* To…
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
To compare the efficacy of alitretinoin and azathioprine in the treatment of severe chronic non-hyperkeratotic hand eczema.
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
The overall aim of this study is to assess the frequency, patient-reported severity and impact of cough, and the distribution of coughing fits during the daytime and nighttime, in a population of patients with non-IPF ILDs.Primary objective: The…